Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

283
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
283
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

48
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
48
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
Drug Therapy01:28

Drug Therapy

114
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
114
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

59
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
59
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

275
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
275

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.

Stem cell research·2026
Same author

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal of cardiac failure·2026
Same author

Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.

JACC. CardioOncology·2026
Same author

Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps.

Blood·2026
Same author

REPLY: Pragmatic Troponin Surveillance for ICI Cardiotoxicity: Impactful Lessons From Real-World Practice.

JACC. CardioOncology·2026
Same author

Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial.

JAMA cardiology·2025

Related Experiment Video

Updated: Oct 5, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.8K

Developing Therapy for Transthyretin Amyloidosis.

Courtney M Campbell1, Kathleen Zhang1, Daniel J Lenihan1

  • 1Cardio-Oncology Center of Excellence, Washington University in St. Louis, Mo.

The American Journal of Medicine
|January 25, 2022
PubMed
Summary

Transthyretin amyloidosis (ATTR) treatments have advanced significantly, offering improved quality and length of life. Emerging therapies promise even brighter outcomes for patients with this condition.

Keywords:
ATTRCardiomyopathyInotersenNeuropathyPatisiranTafamidis

More Related Videos

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.6K
Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers
07:59

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers

Published on: October 29, 2021

3.7K

Related Experiment Videos

Last Updated: Oct 5, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.8K
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.6K
Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers
07:59

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers

Published on: October 29, 2021

3.7K

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Genetics

Background:

  • Transthyretin amyloidosis (ATTR) is an underdiagnosed condition causing cardiomyopathy and neuropathy.
  • Limited therapeutic options were historically available for ATTR.
  • Recent advancements have introduced effective treatments for ATTR.

Purpose of the Study:

  • To review the chronological development of ATTR therapies.
  • To discuss landmark clinical trials in ATTR treatment.
  • To explore emerging therapeutic strategies and future directions for ATTR.

Main Methods:

  • Review of historical and recent clinical trials for ATTR therapies.
  • Analysis of the impact of approved drugs like tafamidis, patisiran, and inotersen.
  • Exploration of novel approaches including drug delivery, antibody therapy, and gene editing.

Main Results:

  • Approved therapies (tafamidis, patisiran, inotersen) demonstrate significant improvements in quality and length of life for ATTR patients.
  • Landmark clinical trials have validated the efficacy of these new treatments.
  • Emerging therapies show potential for further enhancing patient outcomes.

Conclusions:

  • ATTR is a prime example of successful disease-specific therapy development.
  • Understanding disease pathophysiology has led to effective treatments.
  • The future of ATTR therapy is promising, with continued improvement in patient outcomes expected.